People

Eli Rosenberg
Eli S. Rosenberg, PhD
University at Albany School of Public Health, SUNY, Department of Epidemiology and Biostatistics - Associate Professor
Emory University Rollins School of Public Health, Department of Epidemiology and PRISM Health - Adjunct Associate Professor
Education
PhD, Epidemiology, Emory University Rollins School of Public Health
BS, Biometry and Statistics, Cornell University
Research Interests
HIV, HCV, STI epidemiology among PWID and MSM, Surveillance methods, Statistical modeling, Dynamic modeling
BIO
Eli Rosenberg is an associate professor in the Department of Epidemiology and Biostatistics at University at Albany School of Public Health. His research centers on applied and analytic epidemiologic studies that address current public health challenges in HIV, STI, viral hepatitis, and Zika surveillance, prevention, and social determinants. He has specifically focused on sexual and racial minorities, persons who inject drugs, and the infectious disease disparities they face, with considerable effort spent on cohort and modeling studies. Specific methodological interests include surveillance methods, statistical and network modeling, causal inference methods, and development of software to support research studies. This work has occurred across a diverse portfolio of projects supported by NIH, CDC, and the NYS Department of Health.
Projects
Principal Investigator, Estimating the Population Size of Persons Who Inject Drugs in New York. Active
Principal Investigator, Modeling HIV, Viral Hepatitis, STI, and TB to Improve Public Health – CAMP 2.0: The Coalition for Applied Modeling for Prevention. Active
Principal Investigator, Research to Inform Hepatitis C Elimination Strategies in New York State. Completed
Publications

Recent

Bradley H, Austin C, Allen ST, Asher A, Bartholomew TS, Board A, Borquez A, Buchacz K, Carter A, Cooper HLF, Feinberg J, Furukawa N, Genberg B, Gorbach PM, Hagan H, Huriaux E, Hurley H, Luisi N, Martin NK, Rosenberg ES, Strathdee SA, Des Jarlais DC (2022).
A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic
International Journal of Drug Policy, 110, 103889. doi: 10.1016/j.drugpo.2022.103889. PMCID: PMC9574463.

Ansari B, Hart-Malloy R, Rosenberg ES, Trigg M, Martin EG (2022).
Modeling the potential impact of missing race and ethnicity data in infectious disease surveillance systems on disparity measures: Scenario analysis of different imputation strategies
JMIR Public Health and Surveillance, 8 (11), e38037. doi: 10.2196/38037. PMCID: PMC9685511.

Barranco MA, Rosenberg ES, Flanigan C, Shufelt S, Bruce EM, Wilberschied LA, Parker MM, Duncan E, Udo T (2022).
A cross-sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities
Journal of Viral Hepatitis, 29 (11), 994-1003. doi: 10.1111/jvh.13735.

Dorabawila V, Bassett MT, Rosenberg ES (2022).
Risk of infection and hospitalization among children and adolescents in New York after emergence of the SARS-CoV-2 omicron variant – Reply
JAMA, 328 (14), 1460-1461. doi: 10.1001/jama.2022.14484.

Hall EW, Weng MK, Harris AM, Schillie S, Nelson NP, Ortega-Sanchez IR, Rosenthal E, Sullivan PS, Lopman B, Jones J, Bradley H, Rosenberg ES (2022).
Assessing the cost-utility of universal hepatitis B vaccination among adults
Journal of Infectious Diseases, 226 (6), 1041-1051. doi: 10.1093/infdis/jiac088.


Notable

Bradley H, Rosenberg ES, Holtgrave DR (2019).
Data-driven goals for curbing the U.S. HIV epidemic by 2030
AIDS and Behavior, 23 (3), 557-563. doi: 10.1007/s10461-019-02442-7.

Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, Mermin J, Ryerson AB (2018).
Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016
JAMA Network Open, 1 (8), e186371. doi: 10.1001/jamanetworkopen.2018.6371. PMCID: PMC6324373.

Dr. Rosenberg's Google Scholar Profile